Phanes Therapeutics to Present Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting

On April 22, 2026 Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, reported that they will present updated Phase 2 results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting held on May 29 – June 2, 2026 in Chicago. Details of the presentation are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

Date/Time: May 30, 2026, 9:00 AM-12:00 PM CDT

Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary

Abstract #: 4192

Poster #: 175

First Author: Anwaar Saeed, MD, University of Pittsburgh Medical Center

ABOUT SPEVATAMIG

Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with pembrolizumab.

Phanes is conducting clinical trials with spevatamig in multiple cancer indications, including a Phase 2 study evaluating the efficacy of spevatamig in combination with chemotherapy in first-line PDAC patients. As of April 2026, 180 patients globally have been dosed with spevatamig collectively in monotherapy and combination therapy settings.

(Press release, Phanes Therapeutics, APR 22, 2026, View Source [SID1234664699])